Unknown

Dataset Information

0

Increased Activity of a NK-Specific CAR-NK Framework Targeting CD3 and CD5 for T-Cell Leukemias.


ABSTRACT: NK effector cells expressing a CAR construct may be used to target T-lineage markers. In this work, we compared the activity of a NK-specific CAR-NK and a CAR-T framework when expressed on NK effector cells to target CD3 and CD5 in T-cell malignancies. Our results show that CD3-CAR-T is more active than CD5-CAR-T to eliminate malignant T cells in vitro, however, CD3-CAR-T were less efficient to eliminate tumor cells in vivo, while CD5-CAR-T had antitumor activity in a diffuse xenograft model. Lack of in vivo efficacy correlated with downregulation of CD3 levels in target T cells after coculture with CD3-CAR effector cells. The CAR-NK framework greatly improved the efficacy of CARs leading to increased degranulation, cytokine secretion and elimination of the tumor xenograft by CD5-CAR-NK effector cells. Finally, all CAR constructs were similarly effective to eliminate malignant T cells in vitro. Our results show that the NK-CAR framework improves the activity of CARs in NK cells and that CD5 would be a better target than CD3 for T-cell malignancies, as dynamic downregulation of target expression may affect in vivo efficacy.

SUBMITTER: Voynova E 

PROVIDER: S-EPMC8833462 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

Increased Activity of a NK-Specific CAR-NK Framework Targeting CD3 and CD5 for T-Cell Leukemias.

Voynova Elisaveta E   Hawk Nga N   Flomerfelt Francis A FA   Telford William G WG   Gress Ronald E RE   Kanakry Jennifer A JA   Kovalovsky Damian D  

Cancers 20220121 3


NK effector cells expressing a CAR construct may be used to target T-lineage markers. In this work, we compared the activity of a NK-specific CAR-NK and a CAR-T framework when expressed on NK effector cells to target CD3 and CD5 in T-cell malignancies. Our results show that CD3-CAR-T is more active than CD5-CAR-T to eliminate malignant T cells in vitro, however, CD3-CAR-T were less efficient to eliminate tumor cells in vivo, while CD5-CAR-T had antitumor activity in a diffuse xenograft model. La  ...[more]

Similar Datasets

| S-EPMC11898473 | biostudies-literature
| S-EPMC10470138 | biostudies-literature
| S-EPMC6056148 | biostudies-literature
| S-EPMC5762550 | biostudies-literature
| S-EPMC11244547 | biostudies-literature
| S-EPMC6691696 | biostudies-literature
| S-EPMC10296665 | biostudies-literature
| S-EPMC8152219 | biostudies-literature
| S-EPMC7615527 | biostudies-literature
| S-EPMC3810315 | biostudies-literature